Abstract
Plants produce many low molecular mass natural compounds endowed with biological activity. Among them, resveratrol (3,5,4’-trihydroxystilbene) has been demonstrated to be able to affect a plethora of pivotal cellular molecular processes, including transduction pathways and gene expression. These activities result, in turn, in several different cell phenotypes. Particularly, frequent effects of resveratrol treatment appear to be the reduction of growth and the activation of programmed cell death. Accordingly, a number of trials are currently under development to evaluate the possibility of using resveratrol in cancer therapy, both as single agent or in association with other anticancer compounds. However, some reports suggest that, at low concentrations, not only resveratrol does not inhibit the proliferation and/or the survival of cells but, conversely, it induces proliferation and/or protects cells against toxic agents. On the basis of these biphasic effects, it has been proposed that resveratrol belongs to the so-called hormetic compounds.
Hormesis is an expression employed by toxicologists to describe a U-shaped (or J-shaped) dose response characterized by a beneficial effect at low doses and a toxic (or inhibitory) activity at high dose. In this review, we will reappraise data that might suggest or disprove that resveratrol is endowed with clear hormetic properties.
Keywords: Resveratrol, Hormesis, Cancer Treatment, Hormetic Effects, Plant molecules, Biphasic effects.
Current Pharmaceutical Design
Title:Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Volume: 19 Issue: 30
Author(s): Adriana Borriello, Debora Bencivenga, Ilaria Caldarelli, Annunziata Tramontano, Alessia Borgia, Anna Virginia Adriana Pirozzi, Adriana Oliva and Fulvio Della Ragione
Affiliation:
Keywords: Resveratrol, Hormesis, Cancer Treatment, Hormetic Effects, Plant molecules, Biphasic effects.
Abstract: Plants produce many low molecular mass natural compounds endowed with biological activity. Among them, resveratrol (3,5,4’-trihydroxystilbene) has been demonstrated to be able to affect a plethora of pivotal cellular molecular processes, including transduction pathways and gene expression. These activities result, in turn, in several different cell phenotypes. Particularly, frequent effects of resveratrol treatment appear to be the reduction of growth and the activation of programmed cell death. Accordingly, a number of trials are currently under development to evaluate the possibility of using resveratrol in cancer therapy, both as single agent or in association with other anticancer compounds. However, some reports suggest that, at low concentrations, not only resveratrol does not inhibit the proliferation and/or the survival of cells but, conversely, it induces proliferation and/or protects cells against toxic agents. On the basis of these biphasic effects, it has been proposed that resveratrol belongs to the so-called hormetic compounds.
Hormesis is an expression employed by toxicologists to describe a U-shaped (or J-shaped) dose response characterized by a beneficial effect at low doses and a toxic (or inhibitory) activity at high dose. In this review, we will reappraise data that might suggest or disprove that resveratrol is endowed with clear hormetic properties.
Export Options
About this article
Cite this article as:
Borriello Adriana, Bencivenga Debora, Caldarelli Ilaria, Tramontano Annunziata, Borgia Alessia, Pirozzi Virginia Adriana Anna, Oliva Adriana and Ragione Della Fulvio, Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?, Current Pharmaceutical Design 2013; 19 (30) . https://dx.doi.org/10.2174/1381612811319300007
DOI https://dx.doi.org/10.2174/1381612811319300007 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Editorial: Ischemic Stroke Prevention
Current Vascular Pharmacology Tuberculous Pericarditis
Current Cardiology Reviews Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Towards an Experimental and Systems Biology Framework for Cancer Cell Therapeutics
Current Bioinformatics The Diagnosis of Large Airway Pathology and the Role of Rigid Bronchoscopy
Current Respiratory Medicine Reviews Statins: The Holy Grail of Abdominal Aortic Aneurysm (AAA) Growth Attenuation? A Systematic Review of the Literature
Current Vascular Pharmacology Peripartum Cardiomyopathy: Moving Towards a More Central Role of Genetics
Current Cardiology Reviews Association between Fragmentation and Various Substitution Features: A Study on Isoflavonoids Analogues by CID and HCD Using LTQ Orbitrap Mass Spectrometry
Current Traditional Medicine Optimal Management of Hypertension in patients with Ischemic Heart Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Reducing Perioperative Myocardial Infarction with Anesthetic Drugs and Techniques
Current Drug Targets Current Evidence Regarding Low-carb Diets for The Metabolic Control of Type-2 Diabetes
Current Diabetes Reviews An Overview of the Modulatory Effects of Oleic Acid in Health and Disease
Mini-Reviews in Medicinal Chemistry Coffee: A Dietary Intervention on Type 2 Diabetes?
Current Medicinal Chemistry Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science MicroRNAs in C. elegans Aging: Molecular Insurance for Robustness?
Current Genomics Recent Advances in Metabolomics
Current Metabolomics Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating
Current Medicinal Chemistry Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry